ViroMed Overview

  • Founded
  • 1996
Founded
  • Status
  • Public
  • Employees
  • 111
Employees
  • Stock Symbol
  • 084990
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $29.34
  • (As of Friday Closing)

ViroMed General Information

Description

Helixmith Co Ltd, formerly ViroMed Co Ltd is active in the healthcare sector in Korea. The company specializes in developing pharmaceutical products for the treatment of diseases related to peripheral artery, coronary artery, cardiovascular system and neuropathy, cancer and allergy. Its suite of products includes protein/deoxyribonucleic acid (DNA)-based biopharmaceuticals, botanical drugs and natural pharmaceuticals.

Contact Information

Formerly Known As
ViroMedica Pacific
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
KRX
Primary Office
  • 5th Floor, Building 203, SNU
  • No. 599 Gwanak-ro, Gwanak-gu
  • Seoul, 151-747
  • South Korea
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ViroMed Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$29.34 $27.08 $14.94 - $64.36 $836M 28.5M 1.54M -$4.63

ViroMed Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 1,313,852 1,641,322 3,591,715 2,400,037
Revenue 4,488 3,820 2,845 2,785
EBITDA (119,564) (87,717) (26,532) (6,821)
Net Income (128,210) (91,793) (26,138) (5,728)
Total Assets 307,801 320,662 254,166 167,867
Total Debt 120,780 111,104 73,212 10,657
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ViroMed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ViroMed‘s full profile, request access.

Request a free trial

ViroMed Executive Team (4)

Name Title Board Seat Contact Info
Yongsoo Kim President & Chief Executive Officer
Sungchul Kim Co-Founder, Board Member, Chief Financial Officer & Director, Management Support Division
Jong-Mook Kim Ph.D Co-Founder, Director, Development Division & Strategic Business Division & Board Member
Sunyoung Kim Ph.D Co-Founder & Chief Scientific Officer, Research & Development Center
To view ViroMed’s complete executive team members history, request access »

ViroMed Board Members (2)

Name Representing Role Since
Jong-Mook Kim Ph.D ViroMed Co-Founder, Director, Development Division & Strategic Business Division & Board Member 000 0000
Sungchul Kim ViroMed Co-Founder, Board Member, Chief Financial Officer & Director, Management Support Division 000 0000
To view ViroMed’s complete board members history, request access »

ViroMed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViroMed Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 (000 0000000 20-Aug-2018 000000000 00000 00 Buildings and Property 00000000 000 00.0
Genopis 01-Aug-2018 Joint Venture Other Pharmaceuticals and Biotechnology
To view ViroMed’s complete investments history, request access »